BackChengdu Easton Biopharmaceuticals , Ltd. Overview

Chengdu Easton Biopharmaceuticals , Ltd. Receivables

Latest receivables for 688513.SS: $210M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$214.31M
↓ 16.89% YoYΔ $-43.54M vs prior year quarter

Peer trimmed avg / median

Loading

Chengdu Easton Biopharmaceuticals , Ltd. Receivables History

Loading

Chengdu Easton Biopharmaceuticals , Ltd. vs. peers: Receivables Comparison

Loading

Chengdu Easton Biopharmaceuticals , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Chengdu Easton Biopharmaceuticals , Ltd. (688513.SS) FAQ

Chengdu Easton Biopharmaceuticals , Ltd. (688513.SS) currently reports a receivables of $210M as of September 2026. That compares with $260M in the prior-year period — down 16.9% year over year. Use the charts on this page to explore Chengdu Easton Biopharmaceuticals , Ltd.'s receivables history and peer comparisons.

Chengdu Easton Biopharmaceuticals , Ltd.'s receivables decreased from $260M to $210M — a 16.9% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Chengdu Easton Biopharmaceuticals , Ltd. reported $210M in receivables as of September 2026. That compares with $260M in the prior-year period — down 16.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $210M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chengdu Easton Biopharmaceuticals , Ltd., and consider following 688513.SS for alerts when major investors trade the stock.

Chengdu Easton Biopharmaceuticals , Ltd. is classified in the Healthcare sector. On receivables, it currently shows $210M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 688513.SS with unrelated industries.